Clinical Trial Update: A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Siplizumab with Rabbit anti-thymocyte globulin to help kidney transplant acceptance; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection

Drugs mentioned

• Siplizumab (siplizumab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Nefro Avillion Clinical Development, LLC | Conditions: Renal Transplant Failure and Rejection | Phase 2 | Status: NOT_YET_RECRUITING